Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
Noosa News24 hours agoTrump’s trade war puts Australian beef centre stage in Shanghai
-
General23 hours agoCoomalie council dismissed by NT government after investigation finds ‘serious deficiencies’
-
Noosa News22 hours agoHuge suburban crowd cheers for luxury house sale at sausage sizzle auction
-
General22 hours agoSignificant earthquake shakes homes and wakes residents across western NSW